Consumer & Travel Stock News

Upstream Bio second quarter 2026 results highlight $261M cash runway and 2027 Phase 3 targets Immunic's second quarter 2026 loss per share narrows to $0.80 as Phase 3 trials progress Imunon's second quarter 2026 loss of $0.54 per share beat estimates with $1.5M R&D spend CalciMedica misses second quarter 2026 EPS estimates as FDA aligns on pancreatitis trial design Alibaba faces fraud lawsuit over hidden military ties, deadline October 5 DICK'S Sporting Goods Rises, Wells Fargo Cites Nike and $240 Target Nike Teases 'One Piece' Anime Collaboration and Reveals A'ja Wilson Wheaties Partnership Spotify Labels AI Personas, Excluding Them From Recommendations Regeneron sued by investors, alleging misleading Fianlimab melanoma trial data Ferrari target climbs to €400, backed by orders through 2027 Lupin Wins FDA Approval for Lokelma Generic, Targeting $568 Million Market FreeCast Taps Defense and Space Consultant to Chase Government Contracts, but Can a $1.44 Stock Deliver on Billion-Dollar Ambitions? Sanofi Rations Pompe Disease Drugs, Citing FDA Manufacturing Warning Sanofi Rations Pompe Disease Drugs, Following FDA Manufacturing Warning TJX raises 2027 growth targets, fueled by strong quarterly earnings beat Cardinal Health Crushes Earnings and Pledges $6.4 Billion in Buybacks — But Can Specialty-Drug Profits Sustain This Valuation Leap? Zevra Therapeutics Price Targets Climb, Following Massive Q2 Earnings Beat Gyre Therapeutics faces liquidity risks, citing concentrated ownership and loan exposure Hennion & Walsh doubles Ocugen stake, following FDA Phase 3 clearance ImmunityBio Appoints Former World Bank President Jim Yong Kim, Targeting Global Expansion Surf Air Mobility Closes ~$14M Second Tranche of Secured Debenture Financing Cardinal Health Enters $4.0B Credit Agreement, Consolidating and Replacing Previous Facilities AIM CEO Publishes Article Highlighting Ampligen's Potential as Biodefense Therapeutic On Holding's Revenue Miss Sparks a 15% Selloff — Is the Wholesale Slowdown a Speed Bump or a Strategy Flaw? Ultragenyx Settles DOJOLVI® Patent Litigation, Allows Generic Entry in 2033 Connect Biopharma Surges 10% Before Earnings — But Can a Cash-Burning Biotech With No Revenue Justify the Optimism? MiniMed Target Raised to $24, BofA Cites Medtronic Exchange Potential CarGurus Target Hiked to $41, Following Strong Q2 Revenue Beat Achieve Life Sciences Reports Q2 Results, Shifts Manufacturing to United States Sea Ltd Surges 8% Before Earnings — Can Shopee and Garena Justify the Optimism? Damora Therapeutics Lost More Money Than Expected Building Its Blood-Cancer Bet — Can $540 Million in Cash Buy Enough Time? Vera Therapeutics Beat Estimates and Launched Its First Drug — But Can a $425,000 Kidney Therapy Carve Out Space in a Six-Drug Market? Tencent Music Beat Estimates and Still Dropped 4% — What Is the Market Really Pricing In? U.S. Economy Unexpectedly Sheds Jobs in July